McKesson (MCK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Charles Rhyee from TD Cowen maintained a Buy rating on the stock and has a $695.00 price target.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Charles Rhyee has given his Buy rating due to a combination of factors related to McKesson’s performance and outlook. Despite a slight disappointment in the Medical segment’s performance, which missed expectations, Rhyee is optimistic about the company’s strong growth prospects in the US Pharma and RxTS segments.
Rhyee is particularly encouraged by the upward guidance for these segments, indicating robust growth potential. The US Pharma segment showed significant year-over-year growth and confidence in its core distribution trends, while the RxTS segment demonstrated impressive growth, suggesting strong future performance. This optimistic outlook for key business areas supports Rhyee’s Buy rating for McKesson.
In another report released today, Morgan Stanley also reiterated a Buy rating on the stock with a $642.00 price target.